HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: 290/4/F813    most recent 00357.2005v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (5) Citing Articles via Google Scholar Google Scholar Articles by Sugaru, E. Articles by Taiji, M. Search for Related Content PubMed PubMed Citation Articles by Sugaru, E. Articles by Taiji, M.

SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabetic db/db mice

¹Pharmacology Research Laboratories, ²Chemistry Research Laboratories, ³Technology Research and Development Center, and Chemical Synthesis Laboratories, Dainippon Sumitomo Pharma Company, Limited, Drug Research Division, Konohana-ku, Osaka, Japan

Submitted 30 August 2005 ; accepted in final form 7 November 2005

Diabetic nephropathy is currently the most common cause of end-stage renal disease. Diabetic nephropathy patients, whether insulin dependent or not, develop fibrotic changes in glomeruli that manifest as overt nephropathy. Previously, we demonstrated that 5-chloro-2-{(1E)-3-[2-(4-methoxybenzoyl)-4-methyl-1H-pyrrol-1-yl]prop-1-en-1-yl}-N-(methylsulfonyl)benzamide (SMP-534) reduces extracellular matrix (ECM) production induced by transforming growth factor- (TGF-) in vitro and prevents the accumulation of ECM in glomeruli in rat Thy-1 nephritis models. In this study, we examined the long-term effects of SMP-534 on renal insufficiency and glomerulosclerosis in db/db mice, which are models of type 2 diabetes. A diet containing SMP-534 was given to the mice from the age of 9 to 25 wk, and blood and urine analysis were performed at 8, 17, and 25 wk. At the end of study, kidney tissues were analyzed histologically. Treatment with SMP-534 dose dependently suppressed the increase of urinary albumin and type IV collagen excretion in db/db mice. The renal histological analysis showed that SMP-534 dose dependently suppressed the increase of mesangial expansion in the kidney. In the immunohistological analysis, fibronectin and type IV collagen expression were lower in SMP-534-treated db/db mice compared with vehicle-treated db/db mice. This study suggested that SMP-534 ameliorated the increase of ECM production in kidney of db/db mice, possibly through the inhibition of TGF- action. Hence, antifibrotic agents such as SMP-534 might be a new therapeutic option for the treatment of diabetic nephropathy.

urinary type IV collagen; diabetic nephropathy; antifibrotic agent; extracellular matrix; transforming growth factor-

This article has been cited by other articles:

				Y. Huang, W. A. Border, L. Yu, J. Zhang, D. A. Lawrence, and N. A. Noble A PAI-1 Mutant, PAI-1R, Slows Progression of Diabetic Nephropathy J. Am. Soc. Nephrol., February 1, 2008; 19(2): 329 - 338. [Abstract] [Full Text] [PDF]

				S. Liu, L. Shi, and S. Wang Overexpression of upstream stimulatory factor 2 accelerates diabetic kidney injury Am J Physiol Renal Physiol, November 1, 2007; 293(5): F1727 - F1735. [Abstract] [Full Text] [PDF]

				P. Juarez, M. M. Vilchis-Landeros, J. Ponce-Coria, V. Mendoza, R. Hernandez-Pando, N. A. Bobadilla, and F. Lopez-Casillas Soluble betaglycan reduces renal damage progression in db/db mice Am J Physiol Renal Physiol, January 1, 2007; 292(1): F321 - F329. [Abstract] [Full Text] [PDF]